Manufacturing, Specialty Dosage Forms

Exploring Drug Storage, Drug Dosage, and the Supply Chain with Ulrike Lemke (DCAT Week)

May 12, 2023

Dr. Ulrike Lemke, Head of Sterile Fill Finish at Recipharm, sat down with Grant Playter, associate editor, to discuss drug delivery forms.

Moving Forward with GMP 3D Printing for Drug Products

December 03, 2022

Unique dosage forms, personalized medicine, and flexible manufacturing are possible with 3DP.

Aragen to Invest in New Formulation Manufacturing Facility in Hyderabad, India

October 21, 2022

Aragen’s new 12,000 ft² facility will include various dosage form capabilities, including oral solids, liquids, topicals, and films.

Catalent Invests $175 Million to Expand Manufacturing Capabilities and Capacity in US Facility

May 20, 2022

Catalent has announced a $175 million project to expand its manufacturing facility for large scale oral dose forms at its Winchester, Ky, site.

Understanding Pharmaceutical Compounding from Multiple Perspectives

April 02, 2022

Meeting patient needs and achieving high quality are common goals for all stakeholders.

Catalent Completes $30 Million Project for Biopharmaceutical Development and Manufacturing in Limoges, France

March 17, 2022

Catalent has announced the completion of a $30 million project at its facility in Limoges, France focused on biopharmaceutical development and drug product manufacturing.

Spray Drying Finds Growing Use for ASDs

February 01, 2022

CDMOs offer expertise and capacity for spray drying.

Researchers Cite Positive Results in COVID-19 Microneedle Patch Trial

September 24, 2021

Researchers in China report test results for a microneedle patch for COVID-19 vaccine delivery.

Understanding Combination Product Regulations

September 16, 2021

Considering interactions and understanding regulatory requirements are crucial when developing a drug or biologic product for use with a medical device.

SAHPRA Authorizes ImmunityBio to Proceed with Trial of T-Cell Vaccine as Booster Against COVID-19

July 16, 2021

ImmunityBio will proceed with a Phase I/II/III trial in South Africa of their dual-antigen T-cell vaccine as a boost in participants who were previously vaccinated against COVID-19.